Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 10, 2008

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Breast Cancer
Interventions
DRUG

Cetuximab

Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.

DRUG

Ixabepilone

Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.

Trial Locations (1)

77030

The Methodist Hospital Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER

NCT01097642 - Neo-Adjuvant Study in Triple Negative Breast Cancer Patients | Biotech Hunter | Biotech Hunter